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Abstract Breast cancer screening is offered to BRCA1
and BRCA2 mutation carriers from the age of 25 years
because of their increased risk of breast cancer. As ovarian
cancer screening is not effective, risk-reducing salpingho-
oophorectomy (RRSO) is offered after child bearing age.
RRSO before menopause reduces the breast cancer risk as
well as breast density. It can be questioned whether after
premenopausal RRSO, the intensive breast cancer screen-
ing program needs modification. We evaluated the effec-
tiveness of breast cancer screening by clinical breast
examination (CBE), mammography, and MRI in a popu-
lation of 88 BRCA1 and 51 BRCA2 mutation carriers who
had RRSO before the age of 52. Sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) were calculated for each screening modality.
During 422 women years, 14 breast cancers were diag-
nosed; 2 prevalent, 10 screen detected and 2 interval breast
cancers (12 in BRCA1 and 2 in BRCA2 mutation carriers).
Sensitivity, specificity, PPV, and NPV for the combined
screening were 85.7%, 97.6%, 30.0%, and 99.8%, respec-
tively. No tumors were found with CBE, MRI had a sen-
sitivity of 60.0% and mammography of 55.6%. Off all the
tumors, 60% were node positive. Effectiveness of CBE and
mammography was comparable to earlier findings. MRI
screening seemed less effective than earlier findings. After
RRSO, the breast cancer risk in BRCA1 and BRCA2
mutation carriers is still high enough to justify intensive
breast cancer screening with MRI and mammography.
Keywords pBSO  RRSO  BRCA1  BRCA2  Breast
cancer screening  MRI
Introduction
Breast cancer is the most common cancer in women and
the life time risk of developing breast cancer for individual
women in western countries is approximately 12–13% [1].
Women with a family history of breast and/or ovarian
cancer can have substantially higher risks [2]. For women
with a proven BRCA1 or BRCA2 mutation, life time risk
can reach up to 65–80% for breast cancer and 45% for
ovarian cancer by the age of 70 [3, 4]. In the Northern
Netherlands we found a cumulative breast cancer risk of
71.4% (95% CI 67–82%) for BRCA1 mutation carriers and
87.5% (95% CI 82–93%) for BRCA2 mutation carriers by
age of 70 [5]. For ovarian cancer these risks were 58.9%
(95% CI 54–64%) and 34.5% (95% CI 25–44%), respec-
tively [5].
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Female mutation carriers are counseled on different risk
reducing strategies, e.g. screening or prophylactic surgery.
Prophylactic mastectomy strongly reduces the breast can-
cer risk, with about 90% at the age of 70 when conducted at
the age of 38 years [6, 7]. Intensive breast cancer screening
in mutation carriers consists of annual MRI, mammogra-
phy, and clinical breast examination (CBE) and can reach a
sensitivity of more than 90% in finding early stage breast
cancer in mutation carriers [8–12]. For ovarian cancer it
was recently shown that current screening protocols are
ineffective in detecting early stage ovarian cancer in
mutation carriers [13, 14] and the only effective strategy to
prevent ovarian cancer death is a risk reducing salpingo-
oophorectomy (RRSO), which is eventually chosen by
approximately 70% of these women [15, 16].
When this procedure is performed before the age of
50 years, the risk of breast cancer is also reduced, with up
to 50%, depending on the timing of RRSO [17]. Never-
theless, breast cancer screening before the age of 50 is
indicated for women with a breast cancer risk that is 3
times higher than the population risk [18, 19]. BRCA1 and
BRCA2 mutation carriers continue to receive the same
three modality breast screening program after RRSO as
they had before.
Intensive breast cancer screening combining MRI,
mammography, and CBE was proven to be effective in
women at high risk for breast cancer [8–11]. One of the
reasons that MRI was introduced in the screening program
is that mammography is less effective in younger pre-
menopausal women with higher breast density, as is the
case in BRCA1/2 mutation carriers. We hypothesize that
the breast cancer screening protocol might need adaptation
in women after RRSO, because of the lower breast cancer
incidence and the lower breast density after surgical men-
opause. The aim of this study is therefore to determine the




To determine the effectiveness of breast cancer screening in
BRCA1/2 mutation carriers after RRSO, a retrospective
cohort study was performed in BRCA1 or BRCA2 mutation
carriers who underwent a RRSO. All women who were
younger than 52 years of age at RRSO (which is the mean
age at menopause the Netherlands) were included. Results
from subsequent breast cancer screening visits at the family
cancer clinic from the University Medical Centre Groningen
between January 1995 and the end of September 2009 were
analyzed. Women needed to have at least 1 breast eligible
for screening. Women with uni- or bilateral breast con-
serving therapy were included. The use of hormonal
replacement therapy (HRT) was recorded and this was not
an exclusion criterion. Women in whom ovarian cancer was
diagnosed during RRSO were not included in the study.
Surveillance protocol
In our family cancer clinic, RRSO was initially an option
from the age of 35–40 years in BRCA1 mutation carriers
and from the age of 40–45 years in BRCA2 mutation car-
riers. As of 2007, counseling has moved toward a specific
advice to have RRSO around the age of 40, because
ovarian screening appeared not effective in reducing
ovarian cancer death [13, 14]. However, the actual timing
of this decision depends on many personal circumstances
such as previous breast cancer, marital status, previous or
planned pregnancies, and mental acceptance of this defin-
itive procedure. The operative procedure is a daycare sur-
gical procedure, performed by laparoscopy [20].
As of 1995, annual clinical breast examination (CBE) by
oncologic surgeons and nurse practitioners was performed
together with annual mammography from the age of 25.
From 1999, annual MRI was added to the protocol in a part
of our population that participated in the MRISC study [8,
12]. After 2005 it is advised to screen BRCA1/2 mutation
carriers with annual CBE and MRI from age 25 till 60, to
which mammography is added from age 30 onwards [18,
19]. At our centre, MRI and mammography imaging is
ideally performed alternating, i.e. with a 6 month interval.
Variables and endpoints
Information on date of birth, mutation status, personal
oncologic history, date of RRSO, and HRT use were col-
lected for all women. For previous breast cancers, we
collected information about age at diagnosis and therapy.
We reviewed every visit were CBE, mammography and/or
MRI was performed. For all these visits, the reason for
visiting (screening or interval visit due to signs or symp-
toms), the performed diagnostic procedures and the out-
comes of these investigations were collected. The result of
a CBE consult is considered possibly malignant in case of
referral for further investigation. The results of mammog-
raphy and MRI screening are scored in a standardized way,
according to the Breast Imaging Reporting and Data Sys-
tem (BI-RADS) classification. BI-RADS categories vary
between 0 and V and BI-RADS category III or higher are
considered abnormal and indicate further analysis by
ultrasound, MRI and/or tissue sampling [21–23].
When additional diagnostic procedures were performed,
the type of procedure and the findings were noted. Findings
could be ‘‘no malignancy’’ (when no malignancy was
158 Breast Cancer Res Treat (2011) 129:157–164
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found at the additional diagnostic procedures), ‘‘suspect for
malignancy’’ (when more additional investigation was
necessary), and ‘malignancy’’ (as confirmed by biopsy).
For each new breast cancer, tumor size in millimeters and
the presence or absence of lymph node metastases in the
(sentinel) axillary lymph nodes were noted.
Data collection
All relevant data were retrieved from the patients’ hospital
file. Physician’s letters, pathology reports, and imaging
reports were used to collect detailed information about
above mentioned variables and endpoints as defined below.
Data from all consecutive screening visits after RRSO were
entered into an SPSS database. Protection of the patient’s
identity was guaranteed by a patient identification number.
Those numbers were only retraceable to an individual
woman when entered in the hospital database, which is
only accessible for medical staff from the hospital, having
a personal account. Complying with Dutch law, no further
Institutional Review Board approval was needed.
Statistical analysis
Duration of follow-up was calculated for each woman.
Follow-up time was calculated from the date of RRSO to the
following endpoints: date of prophylactic mastectomy, date
of ablation or date of last screening visit. Newly detected
malignancies were defined as prevalent, screen-detected, or
interval cancers. Women were assigned to two groups, based
on their mutation (BRCA1 or BRCA2). Characteristics of
women are presented with median and range when they are
continuous variables. For the other variables numbers are
given and percentage for each mutation group. Differences
between groups were calculated with the Kruskall Wallis
test for continuous variables and v2 tests for the percentages
within mutation groups. To compare the three different
screening modalities, we calculated the sensitivity, speci-
ficity, PPV, and NPV of each screening modality. For these
four outcomes, 95% confidence interval (95% CI) was cal-
culated with the Wilson score interval method. For MRI and
mammography, calculations were made for BI-RADS III
and IV as cut off point for a positive (suspect) test. Statistic
analyses were performed using the software of SPSS 16.0 for
Windows and the VassarStats website [24].
Results
Population characteristics
Of all the mutation carriers who were screened at the
UMCG after RRSO during the study period, 139 women
met our inclusion criteria; 88 (63.3%) BRCA1 mutation
carriers and 51 (36.7%) BRCA2 mutation carriers
(Table 1). BRCA1 mutation carriers had a median age at
RRSO of 40.5 years (range 30–51 years) and BRCA2
mutation carriers had a median age of 42 years (range
33–51 years). Of all women, 18% had a history of breast
cancer, BRCA1 mutation carriers more often than BRCA2
mutation carriers (22.7% and 9.8%, respectively,
P = 0.081). Of all women, BRCA1 mutation carriers
reported significantly more often breast cancer before and
at the age of 45 years than BRCA2 mutation carriers
(80.0% and 40.0%, respectively, P = 0.034).
Screening visits and events during follow-up
The total follow-up in this study was 5064 months (422
women years). The median follow-up was 24.0 months per
woman (range 2–236 months). Women were censored
because of preventive mastectomy (n = 32, 23.0%), breast
cancer (n = 2, 1.4%), referral to another hospital (n = 7,
5.0%) or loss to follow-up (n = 10, 7.2%), the other
women were still in screening after the end of our study
(Table 2). In the women for whom screening ended after
detection of breast cancer, one underwent mastectomy and
one did not undergo further screening after being diag-
nosed with metastases after breast cancer in history.
Malignancies after RRSO
In a total of 1,146 hospital visits, 1,191 screening modal-
ities (CBE, MRI or mammography) were performed in 422
women years. During the total screening period, 14 new
breast cancers were detected: 12 new tumors and two
prevalent tumors, both within 6 months after RRSO. The
median time between RRSO and detection of a new tumor
was 16.5 months. Three patients with a new breast cancer
had a history of breast cancer before RRSO. All of the
three were contra lateral new breast cancers, there were no
local recurrences. In six of the 10 invasive cancers the
lymph nodes were positive. One of the two interval cancers
was node positive. Of the 14 women who were diagnosed
with breast cancer after RRSO, five used HRT. One of
these breast cancers was an interval tumor.
Performance of the screening methods
The performance of the three screening modalities is
summarized in Table 3. The overall sensitivity of the
breast cancer screening program is 85.7%. Two tumors
were interval cancers. No tumors were found by CBE
(Table 3). This gives CBE a sensitivity of 0%, a specificity
of 97.7%, a PPV of 0%, and a NPV of 98.1. In nine women
with breast cancer after RRSO, mammography screening
Breast Cancer Res Treat (2011) 129:157–164 159
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was conducted and five of the nine cancers were identified
by mammography. This gives mammography a sensitivity
of 55.6%, a specificity of 98.4%, a PPV of 50.0%, and a
NPV of 98.8. In 10 women with breast cancer after RRSO
MRI screening was conducted, six of these cancers were
identified by MRI. This gives MRI a sensitivity of 60.0%, a
specificity of 95.9%, a PPV of 35.3%, and a NPV of 98.5%.
Of the two interval tumors, the first (20 mm, node posi-
tive) was detected 5 months after screening CBE. Mam-
mography screening had not yet been performed. This was in
1999 and MRI was not yet part of the screening protocol at
that time. Five years after diagnosis, this patient died of
metastatic disease after a relapse in the mastectomy scar.
The second interval cancer (11 mm, node negative) was
detected by the patient herself 2 weeks after a negative CBE
screening. MRI had not been conducted and the last mam-
mography was 17 months before the new tumor was found.
Screening visits and additional investigation
Of the 138 women who attended screening after RRSO,
127 women had at least one screening CBE, 117 women
had at least one screening mammography and 109 women
had at least one screening MRI (Table 4). The total number
of screening investigations was highest for CBE (583), and
lowest for MRI (278). CBE generated the least additional
diagnostic procedures 3% of the screening visits led to
additional research. For MRI 21% of the screening visits
led to additional research and for mammography, 14% of
the screening visits led to additional research. In the study
Table 1 Characteristics of the women at baseline (N = 139)
BRCA1 (N = 88) BRCA2 (N = 51) Total (N = 139) Statistics
Age at RRSO in years
Median (range) 40.5 (30–51) 42.0 (33–51) 41.0 (30–51) P = 0.059
Previous breast cancer
No 77.3% (68/88) 90.2% (46/51) 82.0% (114/139) P = 0.081
Yes unilateral 15.9% (14/88) 9.8% (5/51) 13.7% (19/139) P = 0.034*
B45 years 85.7% (12/14) 40.0% (2/5) 73.7% (14/19)
Yes bilateral 6.8% (6/88) – 4.3% (6/139)
B45 years 100% (6/6) – 100% (6/6)
Age at diagnosis first breast cancer in years (N = 25)
Median (range) 40.0 (30–49) 46.0 (34–50) 41.0 (30–50) P = 0.143
Breast cancer therapy
BCT unilateral 40.0% (8/20) 80.0% (4/5) 48.0% (12/25) P = 0.427
Mast unilateral 40.0% (8/20) 20.0% (1/5) 36.0% (9/25)
BCT bilateral 15.0% (3/20) – 12.0% (3/25)
BCT and Mast 5.0% (1/20) – 4.0% (1/25)
HRT usea
No 51.2% (41/80) 56.2% (27/48) 53.1% (68/128) P = 0.583
Yes 48.8% (39/80) 43.8% (21/48) 46.9% (60/128)
* P \ 0.05 is significant. Mann–Whitney U test for continuous variables, Pearsons’ v2 test for proportions
BCT breast conserving therapy, Mast mastectomy, if noted as BCT and Mast, 1 breast is treated with BCT and 1 with Mast









Total 3621 1443 5064
Median (range) 29.0 (2–236) 20.0 (2–143) 24.0 (2–236)
Prophylactic mastectomy 20.5% (18/88) 27.5% (14/51) 23.0% (32/139)
Screening ended after breast cancer 2.3% (2/88) – 1.4% (2/139)
Referral to other hospital 6.8% (6/88) 2.0% (1/51) 5.0% (7/139)
Lost to follow-up 9.1% (8/88) 3.9% (2/51) 7.2% (10/139)
Still in screening 61.4% (54/88) 66.7% (34/51) 63.3% (88/139)
160 Breast Cancer Res Treat (2011) 129:157–164
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period, a total of 27 invasive diagnostic procedures (15 fine
needle aspirations and 12 biopsies) were conducted, also
most after MRI. Most additional diagnostic procedures
were performed by using ultrasound (64 times).
While no new cancers where found with CBE, CBE was
carried out as additional investigation 11 times. Of the
tumors found during the screening period, five were pal-
pable when CBE was carried out after suspect findings at
mammography or MRI. In three of these cases, the women
had had a negative CBE screening in the month before the
suspect findings.
When screening consisted of MRI and mammography,
43 screening visits were needed to find 1 new breast cancer.
When CBE was added to the screening, 85 screening visits
were needed to find 1 new breast cancer.
Discussion
In this group of 139 BRCA1/2 mutation carriers who had had
RRSO at a premenopausal age and were under surveillance
at our Family Cancer Clinic, 14 breast cancers were detected
Table 3 Performance of the
screening tests
Cancer present Cancer absent Total
CBE
11 Cancers (2 interval), 9 invasive, 2 DCIS
Positive – 13 13
Negative 11 559 570
Total 11 572 583
Sensitivity: 0% (95% CI 0–32%) PPV: 0% (95% CI 0–28%)
Specificity: 97.7% (95% CI 96–99%) NPV: 98.1% (95% CI 97–99%)
Mammography BI-RADS C III
9 cancers (no interval), 7 invasive, 2 DCIS
Positive 5 5 10
Negative 4 316 320
Total 9 321 330
Sensitivity: 55.6% (95% CI 23–85%) PPV: 50.0% (95% CI 20–80%)
Specificity: 98.4% (95% CI 96–99%) NPV: 98.8% (95% CI 97–100%)
MRI BI-RADS C III
10 cancers (no interval), 7 invasive, 3 DCIS,
Positive 6 11 17
Negative 4 257 261
Total 10 267 278
Sensitivity: 60.0% (95% CI 27–86%) PPV: 35.3% (95% CI 15–61%)
Specificity: 95.9% (95% CI 93–98%) NPV: 98.5% (95% CI 96–100%)
Total screening
14 cancers (2 interval), 11 invasive, 3 DCIS
Positive 12 28 40
Negative 2 1149 1151
Total 14 1177 1191
Sensitivity: 85.7% (95% CI 56–98%) PPV: 30.0% (95% CI 17%–47%)
Specificity: 97.6% (95% CI 97–98%) NPV: 99.8% (95% CI 99–100%)
Table 4 Screening visits and additional research
Screening modality Visits CBE Mammography MRI Ultra sound FNA Biopsy Total
CBE (N = 127) 583 4 2 – 7 2 2 17
Mammography (N = 117) 330 2 3 2 31 3 4 45
MRI (N = 109) 278 5 4 5 27 10 6 57
Total 1191 11 9 7 64 15 12 118
FNA fine needle aspiration
Breast Cancer Res Treat (2011) 129:157–164 161
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in 14 women during 442 women years. There were 2 pre-
valent, 10 screen detected and 2 interval breast cancers. The
program sensitivity was 85.7% and the specificity 97.5%.
For the individual screening modalities, the sensitivity for
CBE was 0% (95% CI 0–32.1%), for mammography 55.6%
(95% CI 22.7–79.9%), and for MRI 60.0% (95% CI
27.4–86.3%). Of all these cancers, 70% was high grade (III)
and 60% of the tumors were node positive.
The program sensitivity of screening with MRI, mam-
mography, and CBE was 85.7% (95% CI 56.2–97.6%).
Earlier studies on screening effectiveness in women at high
risk of breast cancer found sensitivities varying from 91.1%
to 97.7% [8–11], which seems to be higher. Only one study
on the long-term effectiveness of the MRISC study found a
total program sensitivity of 86.6% [12]. The study popula-
tion in these previous studies was more diverse, consisting of
pre- and postmenopausal women. Also, their studies con-
tained mutation carriers, but also women at high risk for
breast cancer without mutation. In our study, all women
were postmenopausal after premenopausal RRSO and they
were all mutation carriers. These factors may have con-
tributed to the differences in effectiveness.
Both Kriege et al. and Rijnberger et al. present results of
the MRISC study. Of the 2,275 participants in these stud-
ies, 148 were from our family cancer clinic [12]. Kriege
et al. noted that 19% of the mutation carriers had RRSO in
history [8]. The amount of women analyzed in both the
MRISC study and our study is probably small.
A main factor that might have contributed to the lower
sensitivity of our surveillance program is that we evaluated
the program sensitivity of the screening over a period of
14 years (1995–2009) during which screening guidelines
changed several times. MRI was offered from 1999 to a
subset of women as part of the MRISC study, and as of 2005
it is offered to all women at high risk. One interval cancer
was found in 1999. Excluding this tumor from the analysis,
would increase the program sensitivity of our screening
from 84.6% to 91.7%, which is in the range that can be
expected. Another consideration is that the four series
mentioned [8–11] are prospective studies with a strict
screening protocol in which every woman receives MRI,
mammography, and CBE at regular intervals. In daily
practice, many factors may influence the regularity of the
screening visits. Planning MRI, mammography, and CBE on
the first visit is sometimes difficult because of agenda and
capacity issues, women do not always attend appointments,
or there may be contra indications for MRI scanning. It is
reasonable to assume that the second interval cancer is
related to ‘‘protocol deviances.’’ This interval cancer was
detected by the patient herself, 2 weeks after a negative CBE
screening, and her last mammography was 17 months
before the new tumor was found. Though this woman was in
screening from 2005 to 2007, she was not screened by MRI.
For the separate screening modalities, the sensitivity of
0% (95% CI 0–32.1%) for CBE found in our study was
comparable to sensitivities of 9.1–17.8% found in other
studies [8, 9]. In general, CBE is considered to have no
additional benefit over mammography, whereas it does
increase the false positive rate [25, 26]. When CBE was
excluded from program sensitivity analyses, sensitivity did
not change. This would mean exclusion of 538 CBE
screenings visits in which no new tumors were detected.
Three of the new tumors found by imaging were palpable
at diagnosis (CBE was conducted as additional research),
while CBE screening within the month before diagnosis
was negative. Also, CBE has proven to be useful in
detecting locoregional recurrences and contralateral breast
cancer in an early stage in women with breast cancer in
history (e.g. after mastectomy, breast conserving therapy,
and radiotherapy) [27]. This indicates that CBE should not
be eliminated from our post-RRSO screening protocol,
especially in women with previous breast cancer.
The sensitivity of 55.6% (95% CI 22.7–79.9%) for
mammography was not significantly different from sensi-
tivities of 32–40% reported in previous studies [8–11].
Long-term follow-up in the MRISC study revealed a sen-
sitivity for mammography of 25% in BRCA1 mutation
carriers [12]. This is much lower than the sensitivity found
in our study, while the majority of tumors we found, were
also in BRCA1 mutation carriers. Due to the lower breast
density after RRSO, we expected that the sensitivity of
mammography in our population would be higher than in
other high risk screening studies. The sensitivity of mam-
mography we found was indeed higher than previously
reported though the difference was not significant. This
may be due to small numbers, or to the fact that about 47%
of the women used HRT after RRSO, which is known to
preserve breast density in postmenopausal women [28].
The sensitivity of 60.0% (95% CI 27–86%) for MRI in
our study was lower (though not significant) than the
sensitivities for MRI reported in previous studies, ranging
from 71.1 to 77.0% [8–10] and significantly lower than the
sensitivity of 90.7% for MRI found by Kuhl et al. [11]. It is
reasonable to suppose that the effectiveness of MRI
screening in daily practice is less than the performance of
MRI screening in prospective trials. At our centre, MRI
software, protocols, and scanners evolved in the past years.
It is likely that MRI sensitivity will improve in the future
along with experience and further improvement of MRI
technology. Another issue is that, 2 of the 4 tumors that
where false negative on MRI were full DCIS. Most tumors
missed on MRI in the MRISC study were also DCIS, which
indicates that MRI is significantly less reliable in detecting
DCIS [26]. This is illustrated by the fact that for invasive
tumors only, MRI sensitivity in our study is 75%, which
lowers to 60.0% (95% CI 27.4–86.3%) when DCIS are
162 Breast Cancer Res Treat (2011) 129:157–164
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included. Rijnsburger et al. found an MRI sensitivity of
66.7% for BRCA1 mutation carriers and 69.2% for BRCA2
mutation carriers, which was significantly higher than the
sensitivity of 25% they found for mammography. In
addition, they showed that MRI enabled the detection of
breast tumors in a more favorable stage than mammogra-
phy. They suggest that MRI screening should be consid-
ered biannually in certain categories [12].
In our study, tumor size was also comparable to other
studies, with 83.3% of the tumors after RRSO being
smaller than 20 mm, compared to percentages ranging
from 75 to 94% in other studies [8–11]. However, 60% of
the tumors in our study were node positive, while others
found percentages of 15.4–36.0% [8–12]. These findings
need further evaluation.
This is the first study on the effectiveness of breast
cancer screening with CBE, mammography, and MRI, in
BRCA1/2 mutation carriers who had undergone RRSO at
premenopausal age, conducted in daily practice and not in
the context of a clinical trial.
It is an interesting finding that MRI sensitivity in this
study was slightly lower than MRI sensitivity in earlier trials.
The question is if this difference is caused by protocol de-
viances in general practice or by effects generated by RRSO.
Also, mammography sensitivity seems to be higher after
RRSO than before. This might be caused by lower breast
density after RRSO, but this should be evaluated during
long term follow-up.
We used the number of new tumors detected by screening
to evaluate the effectiveness of the surveillance program.
Eventually, the purpose of screening is to increase survival
after breast cancer. For evaluating the effect of survival, long
term follow-up is needed. We continue to collect data of this
study population in a prospective database.
To conclude, the sensitivity of three-modality breast
cancer screening in BRCA1/2 mutation carriers after RRSO
is lower than breast cancer screening before RRSO. It is the
lower sensitivity of MRI that contributed largely to the
lower sensitivity of the total screening program, while
mammography sensitivity increases after RRSO. In our
post RRSO population, CBE did not contribute to tumor
detection. Our findings suggest that intensive breast cancer
screening with both MRI and mammography should be
continued in BRCA1/2 mutation carriers, after RRSO.
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